- ISIN
- CH0499880968
- CUSIP
- 049988096
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 16, 1979
Highlights
- Market Cap
- $168.02M
- Enterprise Value
- $363.00M
- EPS (TTM)
- -$0.99
- Total Revenue (TTM)
- $79.18M
- Gross Profit (TTM)
- $71.82M
- EBITDA (TTM)
- -$87.83M
- Year Range
- $0.78 - $4.98
- Target Price
- $7.50
- ROA (TTM)
- -47.00%
- ROE (TTM)
- 63.31%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ADCT Performance Chart
ADC Therapeutics SA (ADCT) is down 69.1% since the beginning of the year. At $1 per share, ADCT is trading 78.1% below its 52-week high of $5. Investors who bought $1,000 worth of ADCT shares 5 years ago would now be looking at an investment worth $44.
Loading charts...
Returns By Period
ADC Therapeutics SA (ADCT) has returned -69.12% so far this year and -60.65% over the past 12 months.
ADC Therapeutics SA
- 1D
- 0.00%
- 1M
- -67.85%
- YTD
- -69.12%
- 6M
- -70.54%
- 1Y
- -60.65%
- 3Y*
- -18.99%
- 5Y*
- -46.46%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ADCT Monthly Returns History
Based on dividend-adjusted daily data since May 15, 2020, ADCT's average daily return is -0.04%, while the average monthly return is -0.77%.
Historically, 38% of months were positive and 62% were negative. The best month was May 2025 with a return of +116.1%, while the worst month was Jun 2026 at -67.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ADCT closed higher 44% of trading days. The best single day was Dec 13, 2023 with a return of +63.1%, while the worst single day was Jun 4, 2026 at -57.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.27% | 13.57% | -8.54% | 0.80% | -10.05% | -67.94% | -69.12% | ||||||
| 2025 | -15.58% | 4.76% | -19.89% | 1.42% | 116.08% | -13.27% | 3.36% | 10.83% | 30.29% | 11.50% | -3.59% | -17.91% | 77.39% |
| 2024 | 87.95% | 54.81% | -7.04% | -1.78% | -22.22% | -7.87% | 5.06% | -12.65% | 8.62% | -10.48% | -14.18% | -17.77% | 19.88% |
| 2023 | 33.07% | -29.55% | -45.83% | -0.51% | 21.13% | -8.51% | -31.16% | -18.92% | -25.25% | -21.96% | 18.57% | 100.00% | -56.77% |
| 2022 | -21.34% | 5.10% | -12.04% | -19.88% | -41.89% | 16.23% | -6.79% | -7.96% | -29.33% | -7.88% | -17.57% | 4.92% | -80.99% |
| 2021 | -10.75% | -6.93% | -8.20% | 0.53% | -11.78% | 12.47% | -13.59% | 38.64% | -6.89% | 6.74% | -23.21% | -9.25% | -36.89% |
Benchmark Metrics
ADC Therapeutics SA has an annualized alpha of -26.57%, beta of 1.24, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since May 15, 2020.
- This stock participated in 243.72% of S&P 500 Index downside but only 50.92% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -26.57%
- Beta
- 1.24
- R²
- 0.05
- Upside Capture
- 50.92%
- Downside Capture
- 243.72%
Return for Risk
Risk / Return Rank
ADCT ranks 12 for risk / return — in the bottom 12% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ADC Therapeutics SA (ADCT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ADCT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.70 | ||
| Sortino ratioReturn per unit of downside risk | -3.30 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.37 | -0.46 |
| Calmar ratioReturn relative to maximum drawdown | -0.76 | 2.78 | -3.54 |
| Martin ratioReturn relative to average drawdown | -2.60 | 12.44 | -15.04 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ADC Therapeutics SA. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ADC Therapeutics SA was 99.08%, occurring on Nov 9, 2023. The portfolio has not yet recovered.
The current ADC Therapeutics SA drawdown is 97.86%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -99.08%Nov 2023 | 3y 4mo | — | 5y 11moJul 2020 - now |
2020 pullback2020 | -7.91%Jun 2020 | 7d | 6d | 13dMay 2020 - Jun 2020 |
2020 pullback2020 | -3.03%Jun 2020 | 2d | 2d | 4dJun 2020 - Jun 2020 |
2020 pullback2020 | -1.20%Jun 2020 | 1d | 4d | 5dJun 2020 - Jun 2020 |
2020 pullback2020 | -1.17%May 2020 | 0s | 3d | 3dMay 2020 - May 2020 |
Drawdown Indicators
| ADCT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.08% | -56.78% | -42.30% |
Max Drawdown (1Y)Largest decline over 1 year | -79.97% | -9.10% | -70.87% |
Max Drawdown (3Y)Largest decline over 3 years | -81.52% | -18.90% | -62.62% |
Max Drawdown (5Y)Largest decline over 5 years | -98.51% | -25.43% | -73.08% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.86% | -1.80% | -96.06% |
Average DrawdownAverage peak-to-trough decline | -77.45% | -10.71% | -66.74% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.34% | 2.03% | +21.31% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ADC Therapeutics SA over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ADC Therapeutics SA is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ADCT relative to other companies in the Biotechnology industry. Currently, ADCT has a P/S ratio of 1.9. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ADCT
Add ADC Therapeutics SA to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ADCT